Analyse Atara Biotherapeutics, Inc. (ATRA) — Kairos Score 59/100

À propos de Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Informations clés

🕴️ Activité des initiés (90 jours)

2 transactions — 1 achats et 1 ventes déclarés par les dirigeants de Atara Biotherapeutics, Inc..

🏦 Hedge Funds

15 fonds institutionnels déclarent une position sur ATRA dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

10 articles récents sur ATRA.

• Atara Biotherapeutics Reports that the Resubmitted Tabelecleucel (Tab-cel®) Biologics License Application Has Been Accepted by the U.S. Food and Drug Administration
• Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.